NAVB Navidea Biopharmaceuticals Inc.

1.17
+0.02  (+2%)
Previous Close 1.15
Open 1.18
Price To Book -29.25
Market Cap 21,152,905
Shares 18,079,406
Volume 34,650
Short Ratio 0.5
Av. Daily Volume 720,922
Stock charts supplied by TradingView

NewsSee all news

  1. Navidea Biopharmaceuticals Announces $1.9 Million Private Placement

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed

  2. Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief

  3. Navidea Biopharmaceuticals Wins Summary Judgment in Ohio

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Court of Common Pleas

  4. Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

    Presentation on Thursday, November 21st at 12:25pm ET Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and

  5. Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results

    Conference Call to be held Thursday, November 7, 2019 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved March 13, 2013.
Lymphoseek
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
NAV4694
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Lymphoseek
Head and Neck Cancer
Phase 2b interim analysis October 29, 2019. Trial to continue enrolling as planned.
NAV3-31 (TC99m-tilmanocept)
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals Announces $1.9 Million Private Placement

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed

  2. Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief

  3. Navidea Biopharmaceuticals Wins Summary Judgment in Ohio

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Court of Common Pleas

  4. Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

    Presentation on Thursday, November 21st at 12:25pm ET Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and

  5. Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results

    Conference Call to be held Thursday, November 7, 2019 at 5:00 pm EDT Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents

  6. Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical stage biopharmaceutical company

  7. Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update

    Conference Call to be held Thursday, November 7, 2019 at 5:00 p.m. (EDT) Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic

  8. Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

    Data Demonstrated Quantitative Repeatability and Stability of Signal Company Continues to Enroll Subjects as Planned to Complete the Phase 2B and Prepare for the Upcoming Phase 3 Trial Navidea Biopharmaceuticals,

  9. Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive

  10. Navidea Biopharmaceuticals Announces Receipt of Notice of Award

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced receipt of the Notice of Award